Zoetis (ZTS) Stock Forecast & Price Target $81.26 -0.07 (-0.08%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$80.75 -0.50 (-0.62%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Zoetis - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating HoldBased on 15 Analyst RatingsSell1Hold7Buy7 Based on 15 Wall Street analysts who have issued ratings for Zoetis in the last 12 months, the stock has a consensus rating of "Hold." Out of the 15 analysts, 1 has given a sell rating, 7 have given a hold rating, and 7 have given a buy rating for ZTS. Consensus Price Target $133.9264.81% Upside According to the 15 analysts' twelve-month price targets for Zoetis, the average price target is $133.92. The highest price target for ZTS is $190.00, while the lowest price target for ZTS is $95.00. The average price target represents a forecasted upside of 64.81% from the current price of $81.26. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for ZTS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Zoetis and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZTS Analyst Ratings Over TimeTypeCurrent Forecast5/25/25 to 5/25/261 Month Ago4/25/25 to 4/25/263 Months Ago2/24/25 to 2/24/261 Year Ago5/25/24 to 5/25/25Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)2 Strong Buy rating(s)Buy7 Buy rating(s)7 Buy rating(s)5 Buy rating(s)6 Buy rating(s)Hold7 Hold rating(s)7 Hold rating(s)7 Hold rating(s)1 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)0 Sell rating(s)Consensus Price Target$133.92$152.25$152.91$212.75Forecasted Upside64.81% Upside30.22% Upside18.81% Upside30.59% UpsideConsensus RatingHoldHoldHoldBuy ZTS Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History ZTS Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Zoetis Stock vs. The CompetitionTypeZoetisMedical CompaniesBroader MarketConsensus Rating Score 2.40 2.30 2.52Consensus RatingHoldHoldModerate BuyPredicted Upside64.81% Upside1,718.96% Upside15.09% UpsideNews Sentiment RatingPositive NewsSee Recent ZTS NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/22/2026 Stifel Nicolaus4 of 5 starsJonathan Block5 of 5 starsLower TargetHold$105.00 ➝ $95.00+18.56%5/18/2026 Citigroup4 of 5 starsDaniel Grosslight1 of 5 starsLower TargetBuy$145.00 ➝ $112.00+44.89%5/15/2026 Morgan Stanley3 of 5 stars Reiterated RatingOverweight$115.00+52.15%5/8/2026 UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAndrea AlfonsoSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetNeutral$130.00 ➝ $99.00+20.28%5/8/2026 JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingChris SchottSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOverweight$190.00 ➝ $130.00+58.80%3/27/2026 Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeHold (C-) ➝ Sell (D+)3/10/2026 Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingMarket Perform3/2/2026 William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingOutperform2/26/2026 BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMark MassaroSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy$160.00+23.89%2/13/2026 Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMichael RyskinSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetNeutral$135.00 ➝ $140.00+11.48%Nobody Understands Why Trump Is Invading Iran (here’s the answer) (Ad)Most investors are reacting to the Iran strikes without understanding the underlying motive driving the decision. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there is a hidden reason behind the bombing - and knowing it could change how you position your money right now.Discover the real reason behind the Iran strikes before markets react1/22/2026 Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid WestenbergSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$190.00 ➝ $135.00+7.93%12/15/2025 The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeBuy12/10/2025 HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Set Target$140.00+21.05%12/8/2025 BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingGlen SantangeloSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageOverweight ➝ Equal Weight$136.00+15.17%11/20/2025 KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSteve DechertSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageSector Weight9/9/2025 ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJasper HellwegSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy$190.00+25.61%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 12:57 PM ET. Should I Buy Zoetis Stock? ZTS Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, May 22, 2026. Please send any questions or comments about these Zoetis pros and cons to contact@marketbeat.com. Zoetis Bull Case Here are some ways that investors could benefit from investing in Zoetis Inc.: The current stock price is around $77.78, which may present a buying opportunity for investors looking for growth in the animal health sector. Recent insider purchases indicate confidence in the company's future, with directors acquiring significant shares, suggesting they believe the stock is undervalued. Zoetis Inc. has a strong market capitalization of approximately $32.61 billion, indicating a solid position in the industry and potential for stability and growth. Analysts have a consensus rating of "Hold" with several firms issuing "Buy" ratings, reflecting positive sentiment and potential for price appreciation. The company has demonstrated resilience with a P/E ratio of 12.90, which is relatively low compared to industry standards, suggesting it may be undervalued. Zoetis Bear Case Investors should be bearish about investing in Zoetis Inc. for these reasons: Recent analyst downgrades, including a reduction in target prices by firms like UBS Group, indicate a cautious outlook on the stock's near-term performance. The company has a high debt-to-equity ratio of 2.80, which may raise concerns about financial leverage and the ability to manage debt effectively. Insider ownership is relatively low at 0.22%, which may suggest a lack of alignment between management and shareholder interests. Zoetis Inc. has experienced fluctuations in its stock price, with a 12-month high of $172.23, indicating potential volatility that could deter risk-averse investors. Some analysts have issued "Sell" ratings, reflecting skepticism about the company's growth prospects in a competitive market. ZTS Forecast - Frequently Asked Questions What is Zoetis' forecast for 2026? According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Zoetis is $133.92, with a high forecast of $190.00 and a low forecast of $95.00. Should I buy or sell Zoetis stock right now? 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There is currently 1 sell rating, 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZTS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZTS, but not buy additional shares or sell existing shares. Does Zoetis's stock price have much upside? According to analysts, Zoetis's stock has a predicted upside of 64.81% based on their 12-month stock forecasts. Has Zoetis been upgraded or downgraded by Wall Street analysts recently? Over the previous 90 days, Zoetis's stock had 1 upgrade and 1 downgrade by analysts. What analysts cover Zoetis? Zoetis has been rated by research analysts at BTIG Research, Citigroup, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Stifel Nicolaus, UBS Group, Weiss Ratings, and William Blair in the past 90 days. Do Wall Street analysts like Zoetis more than its competitors? Analysts like Zoetis more than other "medical" companies. The consensus rating score for Zoetis is 2.40 while the average consensus rating score for "medical" companies is 2.30. Learn more on how ZTS compares to other companies. Stock Forecasts and Research Tools Related Companies BMY Stock Forecast RPRX Stock Forecast JAZZ Stock Forecast CORT Stock Forecast SUPN Stock Forecast NKTR Stock Forecast PRGO Stock Forecast PCRX Stock Forecast OMER Stock Forecast ASMB Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Zoetis RecommendationsStifel NicolausCitigroupMorgan StanleyUBS GroupJPMorgan Chase & Co.Wall Street ZenWeiss RatingsLeerink PartnersWilliam BlairBTIG ResearchBank of AmericaPiper SandlerThe Goldman Sachs GroupHSBCBarclays This page (NYSE:ZTS) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zoetis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zoetis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
